NFKB1 and acute myeloid leukemia: To search for these other autocrine factors that can activate JNK targets and counteract the anti-AML effects of NF-κB inhibitors, we first analyzed the expression profile of inflammatory cytokines in 580 primary human AML samples in our microarray data (Figure 3A).